Physicians views on EGFR wild-type/untested NSCLC treatment
According to surveyed US and European oncologists, improvement in efficacy endpoints are the most influential factors in prescribing decisions for previously treated EGFR wild-type/untested non-small-cell lung cancer (NSCLC).
A news survey fro Decision Resources Group (DRG) also finds that improved median overall survival and increased progression-free survival are the greatest unmet needs in this indication. Surveyed oncologists express enthusiasm for PD-1 monoclonal antibody inhibitors and anticipate that Bristol-Myers Squibb (NYSE: BMY)/Ono Pharmaceutical's (TYO: 4528) nivolumab and Merck & Co's pembrolizumab will demonstrate efficacy advantages over currently available therapies. Interviewed thought leaders also expressed enthusiasm for AstraZeneca's (LSE: AZN) MEK inhibitor selumetinib in combination with docetaxel (generics) for the treatment of KRAS-mutant patients.
Other key findings from the DecisionBase report entitled include:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze